While the news on patients hospitalized with COVID-19 was not as hoped, the ability to positively impact outcomes when identified early is promising.
Eli Lilly Chairman and CEO Dave Ricks told CNBC on Tuesday that he believes the company’s coronavirus antibody treatment will still be beneficial to Covid-19 patients, despite the recent end to a study of the drug in a hospital setting.
To watch the interview, click here.
